利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.04 秒)

    Method of detecting gene polymorphism
    12.
    发明申请
    Method of detecting gene polymorphism 审中-公开
    检测基因多态性的方法

    公开(公告)号：US20060234230A1

    公开(公告)日：2006-10-19

    申请号：US10516038

    申请日：2003-05-29

    申请人： Yusuke Nakamura ,  Akihiro Sekine ,  Aritoshi Iida ,  Susumu Saito

    发明人： Yusuke Nakamura ,  Akihiro Sekine ,  Aritoshi Iida ,  Susumu Saito

    IPC分类号： C12Q1/68 ,  C07H21/04

    CPC分类号： C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6837 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2561/113

    摘要： A method for detecting a genetic polymorphism(s) in a gene encoding cytochrome P450 using as oligonucleotide probes and/or oligonucleotide primers at least one sequence selected from the group consisting of an at least 13 nucleotide sequence within any of the nucleotide sequences as shown in SEQ ID NOS: 1 through 215, said at least 13 nucleotide sequence containing the 21st nucleotide, or a sequence complementary to said at least 13 nucleotide sequence.

    摘要翻译： 用于使用寡核苷酸探针和/或寡核苷酸引物检测编码细胞色素P450的基因中的遗传多态性的方法，所述寡核苷酸探针和/或寡核苷酸引物至少一个选自下列任一核苷酸序列中的至少13个核苷酸序列的序列，如 SEQ ID NO：1至215，所述至少13个核苷酸序列含有第21个核苷酸，或与所述至少13个核苷酸序列互补的序列。

    METHOD FOR DETECTING ARTERIOSCLEROTIC DISEASES ON THE BASIS OF SINGLE NUCLEOTIDE POLYMORPHISM AT HUMAN CHROMOSOME 5P15.3
    14.
    发明申请
    METHOD FOR DETECTING ARTERIOSCLEROTIC DISEASES ON THE BASIS OF SINGLE NUCLEOTIDE POLYMORPHISM AT HUMAN CHROMOSOME 5P15.3 审中-公开
    在人类色素5P15.3单核细胞多态性基础上检测异常性疾病的方法

    公开(公告)号：US20130022975A1

    公开(公告)日：2013-01-24

    申请号：US13579463

    申请日：2011-02-18

    申请人： Kouichi Ozaki ,  Toshihiro Tanaka ,  Yusuke Nakamura

    发明人： Kouichi Ozaki ,  Toshihiro Tanaka ,  Yusuke Nakamura

    IPC分类号： C12Q1/68 ,  C07H21/04

    CPC分类号： C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172

    摘要： An atherosclerotic disease such as myocardial infarction or angina pectoris is detected by analyzing a single nucleotide polymorphism on human chromosome 5p15.3, and by associating results of the analysis with the risk of the onset thereof. Examples of the single nucleotide polymorphism on human chromosome 5p15.3 include a nucleotide corresponding to the nucleotide at position 61 in the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, and a polymorphism at a nucleotide which is in linkage disequilibrium with the above nucleotide.

    摘要翻译： 通过分析人染色体5p15.3上的单核苷酸多态性，并通过将分析结果与其发病风险相关联来检测动脉粥样硬化性疾病如心肌梗塞或心绞痛。 人染色体5p15.3上的单核苷酸多态性的实例包括对应于SEQ ID NO：1，SEQ ID NO：2或SEQ ID NO：3的核苷酸序列中第61位的核苷酸的核苷酸， 与上述核苷酸连接不平衡的核苷酸。

    Physiologically active protein originating in mammals
    15.
    发明授权
    Physiologically active protein originating in mammals 失效
    源自哺乳动物的生理活性蛋白质

    公开(公告)号：US06710171B1

    公开(公告)日：2004-03-23

    申请号：US09380287

    申请日：1999-11-16

    申请人： Yusuke Nakamura ,  Toshihiro Tanaka ,  Shuichi Tsukuda

    发明人： Yusuke Nakamura ,  Toshihiro Tanaka ,  Shuichi Tsukuda

    IPC分类号： C07H2104

    CPC分类号： C07K14/4703 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  C07K14/705 ,  C07K14/82 ,  C07K2319/00

    摘要： The present invention provides novel physiologically active protein molecules originating in mammals, which are specifically expressed in arteriosclerosis and/or coronary restenosis, and are predicted to relate closely to the onset and progress of these diseases; DNAs encoding the protein molecules; antibodies reactive with the molecules; and pharmaceutical compositions comprising the above protein molecule or the antibody. The protein molecules, DNAs, and antibodies are useful for treating and preventing arteriosclerosis.

    摘要翻译： 本发明提供了起源于哺乳动物的新型生理活性蛋白质分子，其在动脉硬化和/或冠状动脉再狭窄中特异性表达，并被预测与这些疾病的发病和进展密切相关; 编码蛋白质分子的DNA; 与分子反应的抗体; 和包含上述蛋白质分子或抗体的药物组合物。 蛋白质分子，DNAs和抗体可用于治疗和预防动脉硬化。

    Method of Detecting Gene Polymorphism, Method of Diagnosing, Apparatus Therefor, and Test Reagent Kit
    16.
    发明申请
    Method of Detecting Gene Polymorphism, Method of Diagnosing, Apparatus Therefor, and Test Reagent Kit 审中-公开
    检测基因多态性的方法，诊断方法，设备及试剂试剂盒

    公开(公告)号：US20080220420A1

    公开(公告)日：2008-09-11

    申请号：US11667971

    申请日：2005-11-18

    申请人： Yusuke Nakamura ,  Toshihiro Tanaka ,  Yozo Ohnishi ,  Nobuhiro Hanafusa ,  Koretsugu Ogata ,  Satoshi Yomota

    发明人： Yusuke Nakamura ,  Toshihiro Tanaka ,  Yozo Ohnishi ,  Nobuhiro Hanafusa ,  Koretsugu Ogata ,  Satoshi Yomota

    IPC分类号： C12Q1/68 ,  C12M1/00

    CPC分类号： C12Q1/6806 ,  B01L3/5027 ,  B01L7/52 ,  B01L2200/16 ,  B01L2300/0816 ,  C12Q1/6858 ,  C12Q2561/101 ,  C12Q2537/143

    摘要： The object of the invention is to carry out typing for multiple SNP sites automatically from the stage of sample preparation. A mixture of sample (2) and PCR reaction solution (4) is subjected to PCR reaction according to a given temperature cycle. After the completion of PCR reaction, invader reagent (6) is added thereto. Subsequently, the reaction mixture having the invader reagent (6) added thereto is added to probe fixing part (8) of typing reaction zone to thereby effect reaction therebetween. Invader probes capable of emitting fluorescence in respective correspondence to multiple SNP sites are separately held on individual sites of the probe fixing part (8), so that the reaction mixture reacts with the invader probes and when SNPs corresponding to the invader probes exist, fluorescence is emitted.

    摘要翻译： 本发明的目的是从样品制备阶段自动进行多个SNP位点的分型。 根据给定的温度循环对样品（2）和PCR反应溶液（4）的混合物进行PCR反应。 PCR反应完成后，加入入侵者试剂（6）。 随后，向其中添加有侵入试剂（6）的反应混合物加入到分型反应区的探针固定部分（8）中，从而在其间进行反应。 能够分别对应于多个SNP位点发射荧光的入侵者探针分别保存在探针固定部分（8）的各个位置，使得反应混合物与入侵者探针反应，并且当存在对应于入侵探针的SNP时，荧光是 发射。

    SEMA5B peptides and vaccines including the same
    17.
    发明授权
    SEMA5B peptides and vaccines including the same 有权
    SEMA5B肽和疫苗包括它们

    公开(公告)号：US09187556B2

    公开(公告)日：2015-11-17

    申请号：US14118693

    申请日：2012-06-07

    申请人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    发明人： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe ,  Gaku Nakayama ,  Yusuke Nakamura

    IPC分类号： C07K14/00 ,  C07K16/18 ,  C07K14/47 ,  G01N33/574 ,  A61K39/00 ,  A61K38/00

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K39/0011 ,  C07K14/4703 ,  G01N33/57492 ,  G01N2333/70539

    摘要： As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译： 如本文详细讨论的，衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL），因此适合用于癌症免疫治疗，尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或若干个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽，多核苷酸，药物或组合物特别用于治疗和/或预防癌症和肿瘤，包括例如食管癌，NSCLC，RCC和SCLC。

    ECT2 peptides and vaccines including the same
    20.
    发明授权
    ECT2 peptides and vaccines including the same 有权
    ECT2肽和疫苗包括它们

    公开(公告)号：US08951975B2

    公开(公告)日：2015-02-10

    申请号：US13638272

    申请日：2011-03-30

    申请人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    发明人： Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC分类号： A61K38/08 ,  A61K38/10 ,  A61K38/00 ,  A61K38/04 ,  C07K7/06 ,  A61K39/00

    CPC分类号： C07K7/06 ,  A61K39/0011 ,  A61K2039/572

    摘要： Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.

    摘要翻译： 衍生自SEQ ID NO：42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗，特别是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸被取代，缺失，插入或添加，只要这些修饰版本保留所需的HLA结合和/或CTL诱导性 的原始序列。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。 本发明的肽，核酸，药物，物质和组合物在治疗癌症和肿瘤方面特别有用，包​​括例如膀胱癌，乳腺癌，子宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌 ，NSCLC，淋巴瘤，胰腺癌，前列腺癌，肾癌和SCLC。